Prediction of drug–drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition

References

• Arand M, Cronin A, Adamska M, Oesch F. (2005). Epoxide hydrolases: structure, function, mechanism, and assay. Meth Enzymol Enzymol 400:569–88.
   PubMed Web of Science ®Google Scholar
• Barr JT, Jones JP. (2013). Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. Drug Metab Dispos 41:24–29.
   PubMed Web of Science ®Google Scholar
• Baxter SW, Choong DY, Campbell IG. (2002). Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer. Cancer Lett 177:75–81.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Tomson T. (1986). Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 11:177–98.
   PubMed Web of Science ®Google Scholar
• Bialer M, Rubinstein A, Raz I, Abramsky O. (1984). Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol 27:501–3.
   PubMed Web of Science ®Google Scholar
• Bonneton J, Genton P, Mesdjian E. (1992). Distribution of carbamazepine and its epoxide in blood compartments in adolescent and adult epileptic patients. Biopharm Drug Dispos 13:411–16.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH. (1979). Valproic acid: in vitro plasma protein binding and interaction with phenytoin. Ther Drug Monit 1:105–16.
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864–73.
   PubMed Web of Science ®Google Scholar
• Davis BB, Thompson DA, Howard LL, et al. (2002). Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA Natl Sci S 99:2222–7.
   PubMed Web of Science ®Google Scholar
• De Berardinis V, Moulis C, Maurice M, et al. (2000). Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 58:542–51.
   PubMed Web of Science ®Google Scholar
• Decker M, Arand M, Cronin A. (2009). Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol 83:297–318.
   PubMed Web of Science ®Google Scholar
• Duan H, Takagi A, Kayano H, et al. (2012). Monoclonal antibodies reveal multiple forms of expression of human microsomal epoxide hydrolase. Toxicol Appl Pharmacol 260:27–34.
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Tomson T, Tybring G, Bertilsson L. (1985). Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 10:80–90.
   PubMed Web of Science ®Google Scholar
• Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug–drug interactions. Xenobiotica 37:1257–94.
   PubMed Web of Science ®Google Scholar
• Enayetallah AE, French RA, Barber M, Grant DF. (2006). Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J Histochem Cytochem 54:329–35.
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Hurst S, Plowchalk D, et al. (2009). Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658–66.
   PubMed Web of Science ®Google Scholar
• Fowler S, Zhang H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug–drug interactions. Aaps J 10:410–24.
   PubMed Web of Science ®Google Scholar
• Frigerio A, Fanelli R, Biandrate P, et al. (1972). Mass spectrometric characterization of carbamazepine-10,11-epoxide, a carbamazepine metabolite isolated from human urine. J Pharm Sci 61:1144–7.
   PubMed Web of Science ®Google Scholar
• Galetin A, Burt H, Gibbons L, Houston JB. (2006). Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166–75.
   PubMed Web of Science ®Google Scholar
• Gertz M, Kilford PJ, Houston JB, Galetin A. (2008). Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535–42.
   PubMed Web of Science ®Google Scholar
• Grime K, Webborn PJ, Riley RJ. (2008). Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. Drug Metab Dispos 36:1670–8.
   PubMed Web of Science ®Google Scholar
• Haj-Yehia A, Bialer M. (1990). Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J Pharm Sci 79:719–24.
   PubMed Web of Science ®Google Scholar
• Hakooz N, Ito K, Rawden H, et al. (2006). Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533–9. 3
   PubMed Web of Science ®Google Scholar
• Hamberger C, Barre J, Brandebourger M, et al. (1987). Progabide and SL 75102 binding to plasma proteins and red blood cells in humans. Int J Clin Pharmacol Ther Toxicol 25:178–84.
   PubMed Web of Science ®Google Scholar
• Heinemann A, Wischhusen F, Puschel K, Rogiers X. (1999). Standard liver volume in the Caucasian population. Liver Transpl Surg 5:366–68.
   PubMedGoogle Scholar
• Houston JB, Galetin A. (2008). Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940–51.
   PubMed Web of Science ®Google Scholar
• Ito K, Hallifax D, Obach RS, Houston JB. (2005). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–44.
   PubMed Web of Science ®Google Scholar
• Kerr BM, Rettie AE, Eddy AC, et al. (1989). Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 46:82–93.
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Gertz M, Houston JB, Galetin A. (2008). Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 36:1194–7.
   PubMed Web of Science ®Google Scholar
• Kitteringham NR, Davis C, Howard N, et al. (1996). Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene. J Pharmacol Exp Ther 278:1018–27.
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Loiseau P, Guyot M, Levy RH. (1993). In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther 54:485–97.
   PubMed Web of Science ®Google Scholar
• Meijer JW, Binnie CD, Debets RM, et al. (1984). Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet 1:802.
   PubMed Web of Science ®Google Scholar
• Morisseau C, Bernay M, Escaich A, et al. (2011). Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies. Anal Biochem 414:154–62.
   PubMed Web of Science ®Google Scholar
• Morisseau C, Hammock BD. (2005). Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45:311–33.
   PubMed Web of Science ®Google Scholar
• Obach RS. (2009). Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 12:81–89.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–55.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 316:336–48.
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Franchi M, Bencini C, Rane A. (1986). Valpromide inhibits human epoxide hydrolase. Br J Clin Pharmacol 22:269–74.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. (2008). Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239–76.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Myllynen P, Taavitsainen P, et al. (2001). Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31:321–43.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Kitteringham NR, Guenthner TM, et al. (1992). An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 43:1675–82.
   PubMed Web of Science ®Google Scholar
• Pisani F, Fazio A, Oteri G, et al. (1986). Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 27:548–52.
   PubMed Web of Science ®Google Scholar
• Pisani F, Haj-Yehia A, Fazio A, et al. (1993). Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia 34:954–59.
   PubMed Web of Science ®Google Scholar
• Poulin P, Hop CE, Ho Q, et al. (2012). Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101:4308–26.
   PubMed Web of Science ®Google Scholar
• Smith CA, Harrison DJ. (1997). Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630–3.
   PubMed Web of Science ®Google Scholar
• Smith PK, Krohn RI, Hermanson GT, et al. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85.
   PubMed Web of Science ®Google Scholar
• Spiegelstein O, Kroetz DL, Levy RH, et al. (2000). Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. Pharm Res 17:216–21.
   PubMed Web of Science ®Google Scholar
• Spina E, Pisani F, Perucca E. (1996). Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 31:198–214.
   PubMed Web of Science ®Google Scholar
• Stresser DM, Blanchard AP, Turner SD, et al. (2000). Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440–48.
   PubMed Web of Science ®Google Scholar
• Templeton I, Peng CC, Thummel KE, et al. (2010). Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 88:499–505.
   PubMed Web of Science ®Google Scholar
• Tomson T, Tybring G, Bertilsson L. (1983). Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther 33:58–65.
   PubMed Web of Science ®Google Scholar
• von Dippe P, Zhu QS, Levy D. (2003). Cell surface expression and bile acid transport function of one topological form of m-epoxide hydrolase. Biochem Biophys Res Commun 309:804–9.
   PubMed Web of Science ®Google Scholar
• Yu Z, Xu F, Huse LM, et al. (2000). Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87:992–8.
   PubMed Web of Science ®Google Scholar
• Zhu Q, von DP, Xing W, Levy D. (1999). Membrane topology and cell surface targeting of microsomal epoxide hydrolase. Evidence for multiple topological orientations. J Biol Chem 274:27898–904.
   PubMed Web of Science ®Google Scholar